Understanding gout and uncontrolled gout:
OVERVIEW OF THE DISEASE STATE, CLINICAL BURDEN, AND TREATMENT LANDSCAPE
Episode 1: What do gout and uncontrolled gout look like?
Episode 1
What do gout and uncontrolled gout look like?
Episode 2
How does gout progress?
Episode 3
What is the role of urate deposition in gout disease progression?
Episode 4
What are the short- and long-term effects of uncontrolled gout, especially...
Episode 5
What are some recommended treatment approaches for chronic gout?
Episode 6
What does the treatment landscape for uncontrolled gout look like?
Episode 7
What are some medication considerations for patients with uncontrolled gou...
Episode 8
Frequently asked questions about gout and uncontrolled goutClinical Perspectives Presented by:
Brian LaMoreaux, MD, MS
Internist and Rheumatologist
Executive Medical Director, Amgen
Chris Doan, MBA, PA-Certified
Senior Director,
Access Strategy, RDBU, Amgen
Program Objectives
In this series, Dr. Brian LaMoreaux explains how to:
Understand the underlying disease and recognize signs of progression in chronic gout and uncontrolled gout
Recognize elements of the clinical burden of chronic gout and the importance of lowering serum uric acid to reduce this burden
Identify urate-lowering therapies and their place in the U.S. gout treatment landscape
Please note that Amgen acquired Horizon Therapeutics on October 6, 2023.
©2024 Horizon Therapeutics USA, Inc.
DA-UNBR-US-02393 02/24